Nuclea Biotechnologies Partners with IBL-America
News Feb 25, 2014
Nuclea Biotechnologies, Inc. has recently announced that Immuno-Biological Laboratories Inc., (IBL-America) would be their primary US distributor for the serum HER-2/neu kits.
IBL-America, based in Minneapolis, MN, is a distributor of high quality diagnostic assays in various areas including autoimmunity, endocrinology, infectious disease, oncology, and neuroscience and offers technical laboratory services as well.
Nuclea is a specialist in serum based oncoprotein diagnostics and offers tests for In Vitro Diagnostic (IVD) and Research Use Only (RUO). Nuclea provides the only FDA-cleared through 510(k) IVD ELISA test for the measurement of serum HER-2/neu in the management and monitoring of women with metastatic breast cancer.
This microtiter based test enables laboratories to measure the level of HER-2/neu in serum in a cost-efficient and validated manner. This test is reimbursed by insurance companies and has a unique CPT code 83950.
Additionally, the two companies will coordinate joint marketing efforts for the serum HER-2/neu kits.
“As we continue to see the market respond to our serum HER-2/neu test, we’ve been securing partners who have strong distribution channels,” said Patrick Muraca, President and CEO of Nuclea. “IBL-America has a proven track record and I’m excited to have them as a partner.”
Mark Kowal, President and CEO of IBL-America stated “We, at IBL-America, are excited about the opportunity to work with the professionals at Nuclea. The HER-2/neu test is an excellent addition to our line of oncology products and we welcome this promising joint venture.”
DNA Methylation Related to Liver Disease in Obese PatientsNews
DNA methylation implicated in initiation of liver fibrosis in non-alcoholic fatty liver diseaseREAD MORE
Diagnosis and Treatment of Heart and Circulatory Diseases a Top Priority for the UKNews
NHS commits to a new focus around heart and circulatory diseases in 10 year planREAD MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018